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ABSTRACT 
Background: Kidney dysfunction is a known risk factor for lower-extremity peripheral 
artery disease (PAD). Although novel filtration markers like cystatin C and beta-2-
microglobulin demonstrate stronger associations with coronary heart disease, stroke, and 
heart failure compared to creatinine-based estimated glomerular filtration rate (eGFRcr), 
whether this pattern holds for PAD is unclear. Also, bone-mineral disorders are important 
complications of kidney dysfunction, but little is known whether bone-mineral 
metabolism (BMM) markers are associated with future PAD risk beyond kidney function. 
Methods: Using data from 12,437 ARIC Study participants free of clinical history of 
PAD at baseline (1990-1992), we first quantified the associations of clinical categories of 
eGFR based on creatinine, cystatin C, and both with PAD risk. Subsequently, we 
evaluated quartiles of these eGFRs, cystatin C, beta-2 microglobulin, as well as BMM 
markers (fibroblast growth factor 23, parathyroid hormone, calcium and phosphorus). 
PAD was defined as hospitalizations with ICD-9 codes for lower-extremity 
atherosclerosis, revascularization and amputation. 
Results: During a median follow-up of 21 years, 471 participants had at least one 
hospitalization with a discharge code for PAD. Low eGFR was significantly associated 
with future PAD risk, independent of traditional cardiovascular risk factors, with slightly 
stronger relationship when cystatin C was used (5.3-7.5 fold higher risk for eGFR <30 
and 2.5-3.7 fold higher risk for eGFR 30-59 vs. eGFR ≥90 ml/min/1.73m2). Novel 
filtration markers, particularly B2M, appeared to have stronger association with incident 
PAD than eGFRcr (adjusted hazard ratios (HRs) for top vs. bottom quartile 2.85 (95% CI: 
2.10- 3.88) vs. 1.30 (95% CI: 0.98-1.71)). The association was consistent after 
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adjustment for BMM markers or restricting to critical limb ischemia as an outcome. 
Among BMM markers, top vs. bottom quartile of phosphorus remained significant for 
PAD risk beyond potential confounders including kidney function (HR 1.43, 95% CI: 
1.08-1.88). 
Conclusions: Kidney dysfunction was significantly associated with future PAD risk 
independently of potential confounders and BMM markers, particularly when cystatin C 
and B2M were taken into account. Among BMM markers, phosphorus was most robustly 
associated with future PAD. Our results suggest the usefulness of novel filtration markers 
for PAD risk assessment and the unique contribution of phosphorus to the 
pathophysiology of PAD.  
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BACKGROUND AND HYPOTHESES 
    Peripheral artery disease (PAD), characterized by atherosclerosis of the lower 
extremities, 1   affects more than 8 million adults in the US, increases the risk of adverse 
health outcomes, 2 and impacts functional performance. 3 PAD is especially an important 
complication for those with chronic kidney disease (CKD), particularly at more advanced 
stages. 4-6  Indeed, the incidence of PAD is higher than that of myocardial infarction and 
stroke among dialysis patients. 7 Of note, mildly to moderately reduced kidney function 
has also been associated with higher risk of PAD in several reports. 8-10  
    Since those reports were published, new equations for estimated glomerular filtration 
rate (eGFR) (e.g., the CKD-EPI equations) or novel filtration markers (e.g., cystatin C 
and β2-microglobulin (B2M)) have demonstrated stronger associations with 
cardiovascular events as compared to the more traditional measure of kidney function, 
creatinine-based eGFR using the MDRD Study equation. 11-16  However, to our 
knowledge, those new equations and novel filtration markers have not been exclusively 
used to assess the risk of incident PAD.   
    Moreover, patients with kidney dysfunction are prone to have abnormal bone-mineral 
metabolism, with altered levels of fibroblast growth factor 23 (FGF-23), parathyroid 
hormone (PTH), serum calcium, and serum phosphorus.17-20  These bone-mineral 
metabolism (BMM) biomarkers are reported to partially explain excess cardiovascular 
risk among persons with CKD 17 21-24 but have not been comprehensively evaluated in the 
context of PAD risk.  
2	
	
    Therefore, we comprehensively assessed the association of future risk of PAD with 
multiple measures of kidney function and BMM using data from a bi-racial community-
based cohort, the Atherosclerosis Risk in Communities (ARIC) study. Our key 
hypotheses are as follows: 1) novel filtration markers are more strongly associated with 
PAD risk compared with creatinine-based eGFR; 2) BMM markers attenuate the 
association between kidney function and PAD risk; 3) and BMM markers are associated 




Study design and population 
    The Atherosclerosis Risk in Communities (ARIC) Study is a prospective cohort of 
15,792 individuals aged from 45 to 64 years at visit 1 (1987-1989) from four 
communities in the US (Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; 
and Washington County, MD). The ARIC Study has conducted follow-up visit 2 (1990- 
1992), visit 3 (1993- 1995), visit 4 (1996-1998) and visit 5 (2011- 2013). We used ARIC 
Study data from visit 2, when all measures of kidney function and BMM markers of 
interest were collected, as baseline in this study. Of the 14,348 participants who attended 
visit 2, we excluded participants with race other than black or white (n= 42), missing data 
on variables of interest (n= 1,832), or with a clinical history of PAD at baseline 
determined by self-report leg artery revascularization at visit 1 and any PAD-related 
hospitalizations prior to the visit of interest at visit 2 (n= 37), yielding a final sample of 





    For this study, participants’ baseline demographic, life-style, and medical 
characteristics were collected at visit 2, if not otherwise specified. Smoking status and 
alcohol drinking status were self-reported and categorized into current, former or never. 
Education information was obtained at visit 1 and was categorized into 3 groups: basic 
(less than high school), intermediate (high school graduate or vocational school), and 
advanced (college, graduate school, or professional school). Body mass index (BMI) was 
calculated as weight in kilogram divided by height in meter squared. Sitting blood 
pressures were measured thrice after a 5-minute rest using a sphygmomanometer, and the 
average of the last two was recorded. Diabetes was diagnosed as fasting plasma glucose 
level ≥126 mg/dL (≥7.0 mmol/L), non-fasting glucose level ≥200 mg/dL (≥11.1 mmol/L), 
self-reported physician diagnosis of diabetes, or use of anti-diabetic medications. 
Prevalent coronary heart disease was defined as cases adjudicated by physician-panel 
between visits 1 and 2 in addition to self-reported clinical history and evidence of prior 
myocardial infarction by electrocardiogram obtained at visit 1. Prevalent stroke was 
similarly defined by self-reported history at visit 1 and any adjudicated cases between 
visits 1 and 2. Medications were determined via self-report usage in the past 2 weeks. All 
serum samples were obtained from participants who were asked to fast for 12 hours 
before their visit and stored at -80 ℃ according to standardized protocols. Total 
cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were measured 
using automated enzymatic procedures, 25 26 and low-density lipoprotein (LDL) 
cholesterol was calculated using the Friedewald equation.27 
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Kidney filtration and bone-mineral metabolism markers 
    eGFR was calculated by the CKD-EPI (CKD Epidemiology Collaboration) 28 - 30 
equations based on demographical variables such as age, sex and race and either or both 
filtration markers, serum creatinine and cystatin C (i.e., eGFRcr, eGFRcys, and eGFRcr-
cys, respectively) . eGFRcr-cys was chosen as the primary kidney filtration marker 
because it is the best available estimate for measured GFR.31  Serum creatinine was 
measured by a modified kinetic Jaffé method, with reliability coefficient of 0.95. Serum 
cystatin C and B2M were measured by a particle-enhanced immunenephelometric assay 
using a BNII nephelometer (Siemens Healthcare Diagnostics), with reliability coefficient 
0.94 for cystatin C and 0.98 for B2M.16 
    FGF-23 was measured in singlicate via a 2-site ELISA (FGF-23 ELISA Kit; Kainos 
Laboratories, Tokyo, Japan) at the Advanced Research and Diagnostic Laboratory, 
University of Minnesota (Minneapolis, MN) in serum samples collected during ARIC 
visit 2, with coefficient of variation (CV) 16.6% from split paired samples and 8.8% from 
internal laboratory quality control samples at 41.4 pg/mL.32 PTH was measured using a 
sandwich immunoassay method on a Roche Elecsys 2010 Analyzer (Roche Diagnostics 
Corporation), with CV 9.7%. Serum calcium and phosphorus were measured using 
colorimetric methods on a Roche Modular P Chemistry Analyzer (Roche Diagnostics 
Corporation), with CV 2.4% and 3.0% for calcium and phosphorus, respectively.  33 
 
Definition of peripheral artery disease (PAD) 
    Based on previous literature,10 34 clinical PAD was identified according to 
hospitalizations with the following ICD-9 discharge codes: 440.20 (atherosclerosis of 
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native arteries of the extremities, unspecified); 440.21 (atherosclerosis of native arteries 
of the extremities with intermittent claudication); 440.22 (atherosclerosis of native 
arteries of the extremities with rest pain); 440.23 (atherosclerosis of native arteries of the 
extremities with ulceration); 440.24 (atherosclerosis of native arteries of the extremities 
with gangrene); 440.29 (other atherosclerosis of native arteries of the extremities); 440.3 
(atherosclerosis of bypass graft of the extremities); 440.4 (Chronic total occlusion of 
artery of the extremities),  38.18 (endarterectomy, lower limb arteries), 39.25 
(intravascular imaging of non-coronary vessel(s) by optical coherence tomography), 
39.29 (other (peripheral) vascular shunt or bypass), 39.50 (angioplasty or atherectomy of 
other non-coronary vessel(s)). Of PAD cases, participants with 440.22 (atherosclerosis of 
native arteries of the extremities with rest pain); 440.23 (atherosclerosis of native arteries 
of the extremities with ulceration); 440.24 (atherosclerosis of native arteries of the 
extremities with gangrene) and those with any of the code above with concurrent ICD-9 
codes of ulcer (707.1), gangrene (785.4), and leg amputation (84.1x) were considered as 
critical limb ischemia (CLI), the most severe form of PAD, with substantial impact on 
patients’ prognosis and quality of life as well as medical expenditure.35-37 Follow-up of 
participants who were free of PAD ended on the date of death, date of last contact, or 
December 31, 2012, whichever came first.  
 
Statistical analysis 
    We compared participants’ baseline characteristics by incident PAD status using two 
sample t test, Wilcoxon rank sum test, and chi square test, as appropriate. Spearman rank 
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correlation coefficient was calculated between kidney filtration markers and BMM 
markers. 
    For longitudinal analyses of incident PAD, we first visualized the potential dose-
response relationship between eGFRs and PAD. We estimated incidence rate according 
to eGFRs as linear splines with six knots at 30, 45, 60, 75, 90 and 105 ml/min/1.73m2, 
adjusting for age, gender and race, in Poisson regression models. Subsequently, we 
examined the impact of potential confounders (details described below) using Cox 
proportional hazards regression models across clinically meaningful categories of eGFRs, 
≥90, 60-<90, 30-<60, and <30 mL/min/1.73 m2.38 Then, for a fair comparison of each of 
the filtration markers, we investigated their quartiles (top quartile as reference for all 
three eGFRs, and the lowest quartile as reference for the rest of markers). BMM markers 
were similarly modeled as quartiles.  
    To acknowledge the attenuation of the associations between filtration markers and 
PAD risk by accounting for BMM markers, we built two models: Model 1 adjusted for 
age, gender, race and ARIC visit center, and traditional confounders at baseline including 
education level, BMI, smoking status, alcohol drinking status, LDL cholesterol level, 
HDL cholesterol level, systolic blood pressure, use of anti-hypertensive medications, use 
of cholesterol-lowering medications, diabetes mellitus, prevalent coronary heart disease 
and prevalent stroke; and Model 2 additionally adjusted for all four BMM markers. For 
the analysis of BMM markers as key exposures, we built three models (denoted as Model 
I to III) to test whether BMM markers are associated with future PAD risk and CLI after 
adjusting for demographics, traditional cardiovascular risk factors, and kidney function. 
Specifically, Model I adjusted for basic demographic confounders including age, gender, 
7	
	
race and ARIC visit center, Model II additionally adjusted for traditional cardiovascular 
risk factors (education level, BMI, smoking and alcohol drinking status, LDL cholesterol 
level, HDL cholesterol level, systolic blood pressure, use of anti-hypertensive medication, 
use of cholesterol-lowering medication, diabetes mellitus, prevalent coronary heart 
disease and prevalent stroke), and Model III further adjusted for eGFRcr-cys. 
    Finally, we conducted subgroup analysis by key demographic and clinical subgroups 
according to age (<65 vs. ≥65 years), gender, race (white vs. black), smoking status 
(current/ former vs. never) and the presence/absence of diabetes mellitus, hypertension 
(defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure≥ 90 mmHg, or 
taking any anti-hypertensive medication), cardiovascular disease (defined as with either 
prevalent coronary heart disease or stroke) at baseline. Potential effect measure 
modification was tested using likelihood ratio test by comparing models with and without 
interaction terms.  
    All analyses were performed using Stata, version 13.0 (StataCorp LP, College Station, 





    The average age of the participants was 56.9 years old (SD 5.7 years), and 56.5% 
(n=7,022) were females, and 75.5% (n=9,388) were whites. As shown in Table 1, 
compared with participants who did not develop incident PAD during the follow-up, 
those who developed PAD were more likely to be older, men, blacks, current smokers, 
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have diabetes and history of stroke and coronary heart disease, higher BMI, SBP, LDL 
cholesterol level and lower HDL cholesterol level, and take cholesterol-lowering 
medication and anti-hypertensive medication, while less likely to be highly educated or 
current drinkers. As shown in Table S1, kidney filtration markers were moderately to 
highly correlated to each other (Spearman rank correlation coefficient (|r|) ranges from 
0.46 to 0.97) but weakly to BMM markers ((|r| ranges from 0.01 to 0.24) (Table S1). 
Correlations between BMM markers were also weak (|r| ranges from 0.08 to 0.20). 
 
Associations of eGFRs with incident PAD and CLI 
    Out of 12,437 participants who were free of PAD at baseline, 471 participants had at 
least one hospitalization with a discharge code for PAD (crude incidence rate: 2.07 
cases/1,000 person-years) during a median follow-up of 21 years, and 171 participants 
had at least one hospitalization with a discharge code for CLI (crude incidence rate: 0.74 
cases/ 1,000 person-years) during a median follow-up of 21 years. Figure 1 shows 
demographically-adjusted incidence rate of PAD according to eGFRs. Regardless of 
equations used, incidence rate of PAD increased steadily below eGFR 105 mL/min/1.73 
m2, with risk gradient of 6-8 fold between eGFR 15 and 105 mL/min/1.73 m2. As seen in 
other cardiovascular outcomes 39, increased incidence rate of PAD was also observed at 
high eGFR, when creatinine was used for estimating GFR (Figure 1A and 1C). This 
pattern was not necessarily evident for eGFRcys (Figure 1B).  
    With clinical categories of eGFR, we confirmed that the associations with PAD risk 
remained significant with a stepwise increased risk with decreasing eGFR categories 
even after accounting for other traditional cardiovascular risk factors (Model 1 in Table 
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2). Specifically, participants with eGFRs <30 mL/min/1.73 m2 had more than 10-fold 
higher risk of incident PAD compared to those in the reference group with eGFR ≥90 
mL/min/1.73 m2. eGFR 30-59 mL/min/1.73 m2 contributed to 2.5-3.8 folds higher risk 
compared to the reference group. Of note, even those with mildly reduced eGFR 60-89 
mL/min/1.73 m2 demonstrated 1.2-1.5 folds higher risk of PAD compared to the 
reference. The hazard ratios (HRs) of PAD in each eGFR category were highest for 
eGFRcr-cys. When we adjusted for all four BMM markers, the attenuation was evident 
only in the category of eGFR <30 mL/min/1.73 m2 (Model 2 in Table 2), but the 
associations still remained significant. The attenuation was mainly driven by PTH (Table 
S2). We observed similar associations when CLI was investigated as the outcome of 
interest (Table 2).  
    According to the association between eGFRs and incident PAD observed in Figure 1 
and Table 2, to obtain reliable estimates in every subgroup, we assessed whether the HR 
of PAD for every 15-unit lower eGFR below 105 ml/min/1.73m2 would differ in 
subgroups by age, sex, race, ever/never smoking, hypertension, diabetes and prevalent 
cardiovascular disease status while adjusting for traditional cardiovascular risk factors 
plus BMM markers (i.e., Model 2) (Table S3). We found consistent association between 
low eGFR and incident PAD in all subgroups. We found significant interaction by ever 
smoking status, diabetes status and hypertension regardless of eGFR equations, but 





Associations of novel filtration markers with incident PAD and CLI 
    When we contrasted novel filtration markers, cystatin C and B2M with eGFRs using 
their quartiles (Table 3), overall, B2M appeared to be most strongly and consistently 
associated with future PAD risk, with 2.5-2.8 fold higher risk between Q4 vs. Q1. Q3 
showed significant results only for B2M, and even its Q2 reached significance for CLI. 
As the PAD risk was lowest in Q2 for eGFRs in several models, we also compared the 
associations with Q2 as reference and confirmed the highest HRs for Q4 of B2M (Table 
S4). We confirmed similar associations for quartiles of cystatin C and B2M across the 
subgroups tested (Table S5).  
       
Associations of BMM markers with incident PAD and CLI 
     Neither of PTH or calcium demonstrated significant associations with PAD risk in all 
Models I to III with Q1 as reference (Table 4). FGF23 was significantly associated with 
incident PAD when adjusted for traditional cardiovascular confounders (Q4 vs. Q1 HR= 
1.41, 95% CI: 1.09 to 1.82 in Model II); however, the association was no longer 
significant after further adjusting for eGFRcr-cys (Model III). Phosphorus was the only 
BMM marker showing significant association with incident PAD, independently of 
traditional cardiovascular risk factors as well as kidney function. The HR of incident 
PAD comparing Q4 to Q1 for phosphorus was 1.52 (95% CI: 1.15 to 2.01) in Model II, 






    In this large community-based cohort study, we observed that reduced eGFR, 
regardless of equations, was associated with future PAD risk in the general population, 
independently of known traditional cardiovascular risk factors. Participants with baseline 
eGFR <30 ml/min/1.73m2 had over 10-fold higher risk of PAD compared to those with 
eGFR ≥90 ml/min/1.73m2. Although weaker, eGFR 30-<60 and 60-<90 still conferred a 
~3-fold and a ~1.5-fold higher risk of future PAD, respectively. Of note, the association 
tended to be more obvious when kidney function was assessed with novel filtration 
markers such as cystatin C and B2M compared to a more conventional measure used in 
clinical practice, eGFRcr. The associations were generally consistent across various 
demographic and clinical subgroups.  The adjustment for BMM markers attenuated the 
associations between kidney function and PAD risk solely when eGFR was below 30 
ml/min/1.73m2. Overall BMM markers were not consistently associated with PAD risk 
even in demographically adjusted models; however, phosphorus was the only marker 
showing significant and consistent associations after accounting for traditional 
cardiovascular risk factors and kidney function. Based on a large sample size and long 
follow-up time, we confirmed similar patterns for CLI, a more severe form of PAD. 
    Several studies have reported the association between kidney function and PAD. 8 10 40- 
45  However, ours is one of a few studies exploring this association in a prospective 
design. 8-10  Using state-of-the-art equations for eGFR and based on adequate PAD cases 
over long follow-up, we were able to quantify the dose-response relationship across 
clinical categories of different eGFR equations. Further, the analysis specific to CLI 
seems unique. Taken altogether, our results clearly support the important contributions of 
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reduced kidney function to the pathophysiology of PAD development. FGF23, PTH, and 
phosphorus are considered as potential mechanisms linking CKD to systemic 
atherosclerosis 22-24 46-48 49 , and our results suggest these BMM markers may partially 
explain this association between CKD and PAD risk when kidney function is severely 
reduced. Other suggested mechanisms linking CKD to atherosclerotic disease include 
inflammation, activated coagulation system, altered homocysteine metabolism, and 
oxidative stress. 50-53 
    Similar to other subtypes of cardiovascular outcomes, we observed that novel filtration 
markers, cystatin C and B2M, are more strongly associated with PAD compared to 
creatinine-based eGFR.16 As discussed previously, there may be kidney-related and non-
kidney elements behind this observation. 54  Specifically, cystatin C and B2M may be 
superior to serum creatinine as filtration markers and indeed are less affected by diet and 
muscle mass.31 In terms of non-kidney elements, cystatin C and B2M are known to be 
linked to inflammation, which may contribute to their strong associations with 
atherosclerotic disease. In addition, B2M has been shown to be indicative of amyloid 
deposition and aggregation in the vessel wall that may contribute to atherosclerosis 
process.55 56 Of note, in a proteomic profiling study, out of ~1,600 protein peaks assessed, 
B2M was found to be most robustly associated with PAD.57 
    We did not observe consistent associations of multiple BMM markers with PAD risk. 
The results for PTH are not necessarily surprising as it was not strongly associated with 
several cardiovascular diseases in a previous report from the ARIC Study.33 FGF-23 has 
been shown to be associated with other subtypes of cardiovascular disease in some 
studies, 58 59 but its association with PAD in our study was no longer significant once 
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adjusting for kidney function. Of those BMM markers, phosphorus was the only 
significant one associated with PAD even after accounting for kidney function. Although 
we are not completely sure about the mechanisms behind this link, our findings are in line 
with a previous study showing the relationship between phosphorus and the risk of 
composite cardiovascular outcomes including coronary heart disease, stroke, PAD, and 
heart failure. 49 Unfortunately, that previous study did not report specific results for PAD. 
Serum phosphorus is known to induce vascular calcification through mineralization of 
the extracellular matrix 60. High phosphorus levels would also inhibit 1,25- dihydroxy 
vitamin D synthesis 24 61, which might subsequently increase vascular calcification. 
Nonetheless, future investigations of the mechanisms linking phosphorus to the 
development of PAD are warranted. 
    Our study results may have some clinical and public health implications. These results 
highlight that reduced kidney function, even at mild to moderate stage, is a risk factor for 
PAD and CLI, independently of well-known traditional cardiovascular risk factors. 
Besides, novel filtration markers may lead to better risk stratification of future PAD. 
Given a possible role for phosphorus in the pathophysiology of PAD suggested in our 
study, future investigations would be warranted regarding whether controlling serum 
phosphorus levels could result in reduction of PAD risk. This may be important since 
there are no established treatments to recover kidney function, but phosphate-binding 
agents are clinically available. In this context, it may be important to recognize that high 
phosphorus diet also contributes significantly to serum phosphorus levels.62 
    Admittedly, this study had several limitations. First, identifying PAD and CLI cases 
based on ICD-9 from hospitalization records limited the sensitivity in outcome 
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ascertainment, though this method is likely to be specific and capture severe symptomatic 
patients requiring hospitalizations. Secondly, kidney function and BMM markers as well 
as other covariates were measured only once at baseline, which may lead to potential 
misclassification. However, this type of misclassification usually results in more 
conservative estimates. Finally, we cannot rule out the possibility of residual confounding, 
as true in any observational studies. 
    In summary, reduced kidney function, even at mild to moderate stages, is 
independently associated with future PAD risk. The associations are more evident when 
novel filtration markers, cystatin C and B2M, are assessed. Although overall the 
associations between BMM markers and PAD risk were not consistent, serum 
phosphorus demonstrates a robust association. These findings confirm the importance of 
PAD as a complication in persons with reduced kidney function. Also, our findings 
suggest usefulness of novel filtration markers for assessing PAD risk and a potential role 







Table 1 Baseline characteristics of participants by incident PAD status 
Variables Total Incident PAD p-value 
 (n=12437) Yes (n=471) No (n=11966)  
Age (years) 56.9 ±  5.7 58.8 ±  5.6 56.8 ±  5.7 <0.001 
 
Male 5415 (43.5) 258 (54.8) 5157 (43.1) <0.001 
 
Blacks 3049 (24.5) 142 (30.1) 2907 (24.3) 0.004 
 
Education     
       Basic 2614 (21.0) 159 (33.8) 2455 (20.5) <0.001 
       Intermediate 5203 (41.8) 177 (37.6) 5026 (42.0)  
       Advanced 4620 (37.2) 135 (28.7) 4485 (37.5)  
     
Body mass index (kg/m
2
) 28.0 ±  5.4 29.0 ±  5.8 27.9 ±  5.4 <0.001 
 
Average systolic blood pressure 
(mmHg) 
121.2 ± 18.6 128.8 ± 20.9 120.9 ± 18.4 <0.001 
 
 
Average diastolic blood pressure 
(mmHg) 
72.1 ± 10.2 72.0 ± 11.2 72.1 ± 10.2 0.943 
 
 
Use of anti-hypertensive 
medication 
3281 (26.4) 212 (45.0) 3069 (25.6) <0.001 
 
 
LDL cholesterol (mg/dL) 133.4 ± 36.7 142.7 ± 40.2 133.1 ± 36.5 <0.001 
 
HDL cholesterol (mmol/L)  1.3 ±  0.4  1.1 ±  0.4  1.3 ±  0.4 <0.001 
 
Use of cholesterol-lowering 
medication 
777 (6.2) 56 (11.9) 721 (6.0) <0.001 
 
 
Smoking    <0.001 
    Current 2723 (21.9) 177 (37.6) 2546 (21.3)  
    Former 4698 (37.8) 174 (36.9) 4524 (37.8)  
 
Alcohol drinking    0.006 
    Current 7058 (56.8) 250 (53.1) 6808 (56.9)  
    Former 2574 (20.7) 125 (26.5) 2449 (20.5)  
 
Prevalent coronary heart disease 683 (5.5) 92 (19.5) 591 (4.9) <0.001 
 
Prevalent stroke 234 (1.9) 23 (4.9) 211 (1.8) <0.001 
 























95.2 ± 17.0 86.7 ± 23.7 95.6 ± 16.6 <0.001 
 
 
Cystatin C (mg/L)  0.9 [0.8- 1.0]  0.9 [0.8- 1.1]  0.9 [0.8- 1.0] <0.001 
 
B2M (mg/L)  1.8 [1.6- 2.1]  2.0 [1.8- 2.4]  1.8 [1.6- 2.1] <0.001 
 
FGF23 (pg/mL) 41.8 [33.9-51.6] 44.7 [35.5-57.0] 41.7 [33.8-51.4] <0.001 
 
PTH (pg/mL) 39.4 [31.2-49.5] 39.7 [29.9-49.6] 39.3 [31.2-49.5] 0.525 
 
Calcium (mg/dL)  9.3 ±  0.4  9.4 ±  0.4  9.3 ±  0.4 0.064 
 
Phosphorus (mg/dL)  3.5 ±  0.5  3.6 ±  0.6  3.5 ±  0.5 0.011 
Note: Values for categorical variables are given as number (percentage); values for continuous variables 
are given as mean ± standard deviation or median [interquartile range]. 
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Table 2 Hazard ratios and 95% confidence intervals for incident PAD, CLI 
according to clinical cutoffs of baseline eGFR using different markers 
Markers CKD Stage eGFR Clinical Cutoffs (mL/min/1.73 m
2
) 
>=90 60-<90 30-<60 <30 
PAD 
Model 1 
eGFRcr Referent 1.24(1.00,1.52)* 2.78(1.81,4.28)*** 11.49(5.91,22.30)*** 
eGFRcys Referent 1.31(1.06,1.63)* 2.53(1.85,3.47)*** 11.24(6.45,19.59)*** 
eGFRcr-cys Referent 1.54(1.25,1.89)*** 3.75(2.62,5.37)*** 13.14(7.13,24.20)*** 
Model 2 
eGFRcr Referent 1.24(1.01,1.53)* 2.69(1.75,4.15)*** 5.34(2.02,14.11)** 
eGFRcys Referent 1.31(1.06,1.62)* 2.52(1.84,3.45)*** 7.05(3.53,14.08)*** 
eGFRcr-cys Referent 1.54(1.25,1.90)*** 3.73(2.59,5.35)*** 7.47(3.24,17.24)*** 
CLI 
Model 1 
eGFRcr Referent 0.79(0.54,1.16) 2.29(1.18,4.45)* 13.13(5.76,29.94)*** 
eGFRcys Referent 1.10(0.77,1.59) 2.30(1.40,3.80)** 13.16(6.19,27.99)*** 
eGFRcr-cys Referent 1.18(0.82,1.69) 3.09(1.73,5.52)*** 12.99(5.68,29.68)*** 
Model 2 
eGFRcr Referent 0.80(0.55,1.17) 2.21(1.14,4.30)* 3.57(0.98,12.96) 
eGFRcys Referent 1.09(0.75,1.56) 2.28(1.38,3.76)** 5.29(1.89,14.79)** 
eGFRcr-cys Referent 1.18(0.82,1.69) 2.97(1.65,5.34)*** 3.56(1.00,12.68)* 
Note:  
*p<0.05, **p<0.01, ***p<0.001 
Model 1 adjusted for age, gender, race, ARIC visit center, education level, BMI, smoking status, alcohol 
drinking status, LDL level, HDL level, systolic blood pressure, anti-hypertensive medication, lowering-
cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke.  







Table 3 Hazard ratios and 95% confidence intervals for incident PAD, CLI 
according to quartiles of kidney function markers (1
st
 quartile as referent) 
Markers Q1 Q2 Q3 Q4 
PAD 
Model 1 
eGFRcr Referent 0.72(0.52,0.99)* 0.96(0.71,1.29) 1.30(0.98,1.71) 
eGFRcys Referent 1.00(0.72,1.37) 1.12(0.82,1.53) 1.83(1.36,2.48)*** 
eGFRcr-
cys 
Referent 0.85(0.62,1.16) 1.05(0.78,1.43) 1.58(1.18,2.12)** 
cystatin C Referent 1.28(0.93,1.75) 1.07(0.76,1.49) 2.08(1.53,2.83)*** 
B2M Referent 1.29(0.93,1.80) 1.75(1.27,2.40)** 2.85(2.10,3.88)*** 
Model 2 
eGFRcr Referent 0.71(0.52,0.97)* 0.93(0.69,1.26) 1.26(0.95,1.66) 
eGFRcys Referent 0.99(0.72,1.37) 1.13(0.83,1.54) 1.76(1.30,2.38)*** 
eGFRcr-
cys 
Referent 0.83(0.60,1.13) 1.04(0.77,1.41) 1.51(1.12,2.02)** 
cystatin C Referent 1.28(0.93,1.75) 1.08(0.77,1.50) 2.03(1.49,2.76)*** 
B2M Referent 1.30(0.93,1.81) 1.76(1.28,2.42)** 2.75(2.02,3.74)*** 
CLI 
Model 1 
eGFRcr Referent 0.58(0.34,1.00)* 1.12(0.70,1.81) 0.97(0.63,1.50) 
eGFRcys Referent 1.03(0.62,1.73) 1.25(0.76,2.05) 1.46(0.89,2.41) 
eGFRcr-
cys 
Referent 1.06(0.65,1.72) 1.09(0.67,1.78) 1.39(0.87,2.23) 
cystatin C Referent 1.41(0.86,2.31) 1.18(0.70,1.98) 1.69(1.03,2.76)* 
B2M Referent 1.86(1.08,3.19)* 2.39(1.41,4.06)** 2.79(1.66,4.70)*** 
Model 2 
eGFRcr Referent 0.56(0.33,0.97)* 1.07(0.66,1.72) 0.88(0.57,1.37) 
eGFRcys Referent 1.04(0.62,1.75) 1.26(0.77,2.07) 1.34(0.81,2.20) 
eGFRcr-
cys 
Referent 1.02(0.62,1.66) 1.07(0.65,1.74) 1.25(0.77,2.01) 
cystatin C Referent 1.43(0.87,2.35) 1.20(0.71,2.02) 1.57(0.95,2.58) 
B2M Referent 1.89(1.10,3.26)* 2.42(1.42,4.11)** 2.55(1.51,4.31)*** 
Note: 
*p<0.05, **p<0.01, ***p<0.001 
Model 1 adjusted for age, gender, race, ARIC visit center, education level, BMI, smoking status, alcohol 
drinking status, LDL level, HDL level, systolic blood pressure, anti-hypertensive medication, lowering-
cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke.  
Model 2 adjusted for covariates in Model 1 plus FGF23, PTH, calcium and phosphorus. 
Quartiles for kidney function markers: 
eGFRcr (mL/min/1.73 m2): Q1: ≥ 105.64, Q2: 97.44-<105.64, Q3: 88.68-< 97.44, Q4: < 88.68 
eGFRcys (mL/min/1.73 m2): Q1: ≥ 104.88, Q2: 93.75-<104.88, Q3: 79.05-< 93.75, Q4: < 79.05 
eGFRcr-cys (mL/min/1.73 m2): Q1: ≥106.64, Q2: 96.69-<106.64, Q3: 85.19-< 96.69, Q4: < 85.19 
cystatin C (mg/L): Q1: <0.76, Q2: 0.76-< 0.85, Q3: 0.85-< 0.97, Q4: ≥0.97 
B2M (mg/L): Q1: <1.62, Q2: 1.62-< 1.84, Q3: 1.84-< 2.11, Q4: ≥2.11 
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Table 4 Hazard ratios and 95% confidence intervals for incident PAD, CLI 
according to quartiles of bone-mineral metabolism markers (1
st
 quartile as referent) 
Markers Q1 Q2 Q3 Q4 
PAD 
Model I 
FGF23 Referent 0.95(0.72,1.25) 1.09(0.83,1.43) 1.58(1.23,2.02)*** 
PTH Referent 0.64(0.49,0.83)** 0.86(0.67,1.10) 0.80(0.62,1.03) 
Calcium Referent 1.07(0.81,1.40) 1.16(0.91,1.48) 1.22(0.94,1.57) 
Phosphorus Referent 1.09(0.84,1.40) 1.10(0.85,1.41) 1.62(1.23,2.13)** 
Model II 
FGF23 Referent 0.97(0.74,1.29) 1.02(0.78,1.33) 1.41(1.09,1.82)** 
PTH Referent 0.74(0.57,0.97)* 0.96(0.75,1.23) 0.92(0.71,1.20) 
Calcium Referent 0.95(0.72,1.25) 1.07(0.84,1.36) 0.95(0.73,1.23) 
Phosphorus Referent 1.16(0.90,1.50) 1.10(0.86,1.42) 1.52(1.15,2.01)** 
Model III 
FGF23 Referent 0.94(0.71,1.24) 0.96(0.73,1.26) 1.16(0.89,1.51) 
PTH Referent 0.73(0.56,0.95)* 0.97(0.76,1.25) 0.86(0.66,1.12) 
Calcium Referent 0.95(0.73,1.25) 1.04(0.82,1.33) 0.89(0.68,1.15) 
Phosphorus Referent 1.16(0.90,1.50) 1.11(0.86,1.43) 1.43(1.08,1.88)* 
CLI 
Model I 
FGF23 Referent 0.70(0.44,1.11) 0.95(0.61,1.45) 1.31(0.88,1.95) 
PTH Referent 0.78(0.51,1.21) 0.90(0.60,1.37) 0.67(0.43,1.04) 
Calcium Referent 1.07(0.68,1.69) 1.00(0.66,1.52) 1.29(0.85,1.94) 
Phosphorus Referent 1.05(0.69,1.62) 1.01(0.66,1.54) 1.51(0.96,2.35) 
Model II 
FGF23 Referent 0.70(0.43,1.11) 0.84(0.55,1.30) 1.06(0.71,1.60) 
PTH Referent 0.88(0.57,1.36) 0.96(0.63,1.46) 0.73(0.46,1.14) 
Calcium Referent 0.92(0.58,1.46) 0.94(0.61,1.43) 0.94(0.61,1.45) 
Phosphorus Referent 1.18(0.76,1.83) 1.09(0.71,1.67) 1.59(1.01,2.51)* 
Model III 
FGF23 Referent 0.68(0.42,1.09) 0.81(0.53,1.25) 0.90(0.59,1.38) 
PTH Referent 0.86(0.55,1.33) 0.97(0.64,1.47) 0.67(0.42,1.05) 
Calcium Referent 0.94(0.59,1.49) 0.94(0.62,1.43) 0.93(0.61,1.42) 
Phosphorus Referent 1.19(0.77,1.84) 1.13(0.74,1.73) 1.54(0.98,2.42) 
Note: 
*p<0.05, **p<0.01, ***p<0.001 
Model I adjusted for age, gender, race and ARIC visit center.  
Model II adjusted for covariates in Model I plus education level, BMI, smoking status, alcohol drinking 
status, LDL level, HDL level, systolic blood pressure, anti-hypertensive medication, lowering-cholesterol 
medication, diabetes, prevalent coronary heart disease and prevalent stroke.   
Model III adjusted for covariates in Model II plus eGFRcr-cys.  
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Quartiles for BMM markers: 
FGF23 (pg/mL): Q1: <33.89, Q2: 33.89-<41.79, Q3: 41.79-< 51.57, Q4: ≥ 51.57 
PTH (pg/mL): Q1: <31.20, Q2: 31.20-<39.38, Q3: 39.38-< 49.47, Q4:  ≥49.47 
Calcium (mg/dL): Q1: <9.2, Q2: 9.2-<9.4, Q3: 9.4-< 9.7, Q4:  ≥9.7 









Table S 1 Spearman rank correlation coefficients between filtration markers and 









B2M FGF23 PTH Ca P 
eGFRcr  1.000         
eGFRcys  0.519  1.000        
eGFRcr-cys  0.809  0.905  1.000       
cystatin C -0.516 -0.968 -0.898  1.000      
B2M -0.457 -0.772 -0.727  0.762 1.000     
FGF23 -0.163 -0.244 -0.238  0.249 0.237 1.000    
PTH -0.003 -0.022 -0.007 -0.005 0.015 0.081  1.000   
Ca -0.047 -0.123 -0.101  0.110 0.096 0.129 -0.091 1.000  
P  0.078 -0.042  0.019 -0.022 0.016 0.110 -0.134 0.201 1.000 
Abbreviations:  
B2M: beta-2 microglobulin, FGF23: fibroblast growth factor 23, PTH: parathyroid hormone,  





Table S 2 Hazard ratios and 95% confidence intervals for incident PAD and CLI 
according to clinical cutoffs of baseline eGFR using different markers with 
adjustment for BMM markers in turn 
	
Marker Model CKD Stage eGFR Clinical Cutoffs (mL/min/1.73 m
2
) 
>=90 60-<90 30-<60 <30 




1 Referent 1.24(1.00,1.52) 2.78(1.81,4.28) 11.49(5.91,22.30) 
2.a Referent 1.24(1.00,1.52) 2.78(1.81,4.28) 11.28(5.73,22.19) 
2.b Referent 1.23(1.00,1.52) 2.77(1.80,4.26) 7.98(3.32,19.15) 
2.c Referent 1.24(1.01,1.53) 2.79(1.81,4.30) 11.26(5.77,21.97) 
2.d Referent 1.24(1.00,1.52) 2.70(1.75,4.17) 8.74(4.40,17.34) 




1 Referent 1.31(1.06,1.63) 2.53(1.85,3.47) 11.24(6.45,19.59) 
2.a Referent 1.31(1.06,1.63) 2.53(1.85,3.47) 11.08(6.31,19.44) 
2.b Referent 1.31(1.06,1.62) 2.51(1.83,3.44) 8.96(4.68,17.13) 
2.c Referent 1.33(1.07,1.64) 2.55(1.86,3.50) 11.19(6.41,19.52) 
2.d Referent 1.30(1.05,1.61) 2.52(1.84,3.45) 9.13(5.15,16.20) 




1 Referent 1.54(1.25,1.89) 3.75(2.62,5.37) 13.14(7.13,24.20) 
2.a Referent 1.54(1.25,1.89) 3.75(2.62,5.37) 12.94(6.96,24.08) 
2.b Referent 1.53(1.24,1.89) 3.72(2.59,5.33) 10.14(4.71,21.85) 
2.c Referent 1.55(1.26,1.91) 3.80(2.65,5.46) 12.83(6.94,23.72) 
2.d Referent 1.53(1.24,1.88) 3.70(2.58,5.30) 10.39(5.53,19.52) 
2 Referent 1.54(1.25,1.90) 3.73(2.59,5.35) 7.47(3.24,17.24) 





1 Referent 0.79(0.54,1.16) 2.29(1.18,4.45) 13.13(5.76,29.94) 
2.a Referent 0.79(0.54,1.16) 2.30(1.18,4.45) 12.92(5.59,29.86) 
2.b Referent 0.79(0.54,1.16) 2.27(1.17,4.39) 6.22(2.03,19.05) 
2.c Referent 0.80(0.54,1.17) 2.29(1.18,4.43) 12.80(5.53,29.64) 
2.d Referent 0.80(0.54,1.17) 2.25(1.16,4.38) 9.48(4.00,22.49) 





1 Referent 1.10(0.77,1.59) 2.30(1.40,3.80) 13.16(6.19,27.99) 
2.a Referent 1.10(0.76,1.58) 2.30(1.40,3.79) 12.97(6.05,27.79) 
2.b Referent 1.08(0.75,1.56) 2.24(1.36,3.69) 7.74(3.07,19.56) 
2.c Referent 1.11(0.77,1.60) 2.31(1.40,3.81) 12.89(6.04,27.52) 
2.d Referent 1.10(0.76,1.58) 2.34(1.42,3.86) 10.08(4.60,22.10) 







1 Referent 1.18(0.82,1.69) 3.09(1.73,5.52) 12.99(5.68,29.68) 
2.a Referent 1.18(0.82,1.69) 3.09(1.73,5.53) 12.75(5.51,29.46) 
2.b Referent 1.16(0.81,1.67) 3.01(1.68,5.39) 6.20(2.07,18.57) 
2.c Referent 1.19(0.83,1.70) 3.11(1.74,5.57) 12.42(5.37,28.72) 
2.d Referent 1.19(0.83,1.70) 3.02(1.68,5.43) 9.70(4.11,22.88) 
2 Referent 1.18(0.82,1.69) 2.97(1.65,5.34) 3.56(1.00,12.68) 
Note:  
Model 1 adjusted for age, gender, race and ARIC visit center, education level, BMI, smoking status, 
alcohol drinking status, LDL level, HDL level, systolic blood pressure, anti-hypertensive medication, 
lowering-cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke.   
Model 2.a adjusted for covariates in Model 1 plus FGF23.  
Model 2.b adjusted for covariates in Model 1 plus PTH.  
Model 2.c adjusted for covariates in Model 1 plus calcium.  
Model 2.d adjusted for covariates in Model 1 plus phosphorus. 






Table S 3 Subgroup analyses on the association between incident PAD and every 15-
unit decrease in eGFRs 
Outcome Marker Demographical 
factor 





PAD eGFRcr Age   0.033 
   ≥65 1.36 (1.23,1.51)  
   <65 1.45 (1.32,1.58)  
      
PAD eGFRcr Sex   0.833 
   Male 1.42 (1.26,1.61)  
   Female 1.36 (1.21,1.54)  
      
PAD eGFRcr Race   0.708 
   Black 1.44 (1.25,1.65)  
   White 1.36 (1.21,1.54)  
      
PAD eGFRcr Ever smoking   0.000 
   Yes 1.32 (1.20,1.45)  
   No 1.52 (1.37,1.67)  
      
PAD eGFRcr Diabetes   0.030 
   Yes 1.32 (1.17,1.49)  
   No 1.46 (1.30,1.65)  
      
PAD eGFRcr Hypertension   0.000 
   Yes 1.34 (1.22,1.47)  
   No 1.49 (1.35,1.63)  
      
PAD eGFRcr Prevalent CVD   0.187 
   Yes 1.26 (1.07,1.49)  
   No 1.43 (1.29,1.59)  
      
PAD eGFRcys Age   0.099 
   ≥65 1.36 (1.23,1.49)  
   <65 1.43 (1.32,1.55)  
      
PAD eGFRcys Sex   0.961 
   Male 1.38 (1.23,1.53)  
   Female 1.38 (1.24,1.54)  
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PAD eGFRcys Race   0.253 
   Black 1.38 (1.22,1.57)  
   White 1.37 (1.24,1.52)  
      
PAD eGFRcys Ever smoking   0.000 
   Yes 1.37 (1.26,1.49)  
   No 1.55 (1.42,1.70)  
      
PAD eGFRcys Diabetes   0.023 
   Yes 1.29 (1.15,1.45)  
   No 1.45 (1.31,1.61)  
      
PAD eGFRcys Hypertension   0.000 
   Yes 1.33 (1.22,1.45)  
   No 1.47 (1.35,1.60)  
      
PAD eGFRcys Prevalent CVD   0.238 
   Yes 1.25 (1.07,1.46)  
   No 1.43 (1.30,1.57)  
      
PAD eGFRcr-
cys 
Age   0.044 
   ≥65 1.43 (1.29,1.58)  
   <65 1.51 (1.39,1.65)  
      
PAD eGFRcr-
cys 
Sex   0.976 
   Male 1.47 (1.31,1.65)  
   Female 1.45 (1.29,1.63)  
      
PAD eGFRcr-
cys 
Race   0.376 
   Black 1.48 (1.30,1.69)  
   White 1.43 (1.28,1.60)  
      
PAD eGFRcr-
cys 
Ever smoking   0.000 
   Yes 1.42 (1.30,1.55)  
   No 1.62 (1.48,1.78)  








Diabetes   0.016 
   Yes 1.36 (1.21,1.53)  
   No 1.54 (1.38,1.73)  
      
PAD eGFRcr-
cys 
Hypertension   0.000 
   Yes 1.41 (1.29,1.54)  
   No 1.55 (1.42,1.70)  
      
PAD eGFRcr-
cys 
Prevalent CVD   0.190 
   Yes 1.29 (1.09,1.52)  
   No 1.52 (1.38,1.68)  
Note:  
a. The unit for eGFRs is mL/min/1.73 m2. 
HRs were calculated from linear combinations of coefficients in the model with interaction terms based on 
model 2, and p-value was obtained from likelihood ratio test comparing models with and without the 
interaction term. 
Specifically,  
(1) when stratifying by age, covariates in the model included main effects of the binary age category and 
both of the two slopes as well as their interactions, gender, race, ARIC visit center, education level, BMI, 
smoking status, alcohol drinking status, LDL level, HDL level, systolic blood pressure, anti-hypertensive 
medication, lowering-cholesterol medication, diabetes, prevalent coronary heart disease and prevalent 
stroke, plus FGF23, PTH, calcium and phosphorus; 
(2) when stratifying by gender, covariates in the model included main effects of gender and both of the two 
slopes as well as their interactions, age, race, ARIC visit center, education level, BMI, smoking status, 
alcohol drinking status, LDL level, HDL level, lowering-cholesterol medication, diabetes, prevalent 
coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; 
(3) when stratifying by race, covariates in the model included main effects of race and both of the two 
slopes as well as their interactions, age, gender, ARIC visit center, education level, BMI, smoking status, 
alcohol drinking status, LDL level, HDL level, lowering-cholesterol medication, diabetes, prevalent 
coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; 
(4) when stratifying by ever smoking, covariates in the model included main effects of binary smoking 
category (ever vs. never smoking) and both of the two slopes as well as their interactions, age, gender, race, 
ARIC visit center, education level, BMI, alcohol drinking status, LDL level, HDL level, systolic blood 
pressure, anti-hypertensive medication, lowering-cholesterol medication, diabetes, prevalent coronary heart 
disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; 
(5) when stratifying by diabetes status, covariates in the model included main effects of binary indicator for 
diabetes and both of the two slopes as well as their interactions, age, gender, race, ARIC visit center, 
education level, BMI, smoking status, alcohol drinking status, LDL level, HDL level, systolic blood 
pressure, anti-hypertensive medication, lowering-cholesterol medication, prevalent coronary heart disease 
and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; 
(6) when stratifying by hypertension status, covariates in the model included main effects of hypertension 
and each of the two slopes as well as their interactions, age, gender, race, ARIC visit center, education level, 
BMI, smoking status, alcohol drinking status, LDL level, HDL level, lowering-cholesterol medication, 
diabetes, prevalent coronary heart disease and prevalent stroke, plus FGF23, PTH, calcium and phosphorus; 
(7) when stratifying by prevalent CVD, covariates in the model included main effects of prevalent CVD 
and each of the two slopes as well as their interactions, age, gender, race, ARIC visit center, education level, 
BMI, smoking status, alcohol drinking status, LDL level, HDL level, systolic blood pressure, anti-




Table S 4 Hazard ratios and 95% confidence intervals for incident PAD, CLI 
according to quartiles of kidney function markers (2
nd
 quartile as referent) 
Markers Q1 Q2 Q3 Q4 
PAD 
Model 1 
eGFRcr 1.40(1.03,1.89)* Referent 1.27(0.95,1.69) 1.82(1.40,2.38)*** 
eGFRcys 1.03(0.75,1.43) Referent 1.17(0.88,1.57) 1.97(1.51,2.59)*** 
eGFRcr-
cys 
1.12(0.82,1.54) Referent 1.28(0.96,1.71) 1.92(1.46,2.51)*** 
cystatin C 0.71(0.52,0.97)* Referent 0.82(0.62,1.08) 1.66(1.29,2.14)*** 
B2M 0.83(0.60,1.15) Referent 1.42(1.06,1.89)* 2.29(1.74,3.01)*** 
Model 2 
eGFRcr 1.44(1.05,1.99)* Referent 1.40(1.03,1.89)* 1.88(1.41,2.51)*** 
eGFRcys 1.03(0.74,1.43) Referent 1.19(0.89,1.60) 1.88(1.43,2.48)*** 
eGFRcr-
cys 
1.15(0.84,1.59) Referent 1.31(0.98,1.75) 1.85(1.40,2.43)*** 
cystatin C 0.70(0.51,0.97)* Referent 0.83(0.62,1.10) 1.59(1.23,2.06)*** 
B2M 0.84(0.60,1.17) Referent 1.44(1.08,1.93)* 2.21(1.68,2.92)*** 
CLI 
Model 1 
eGFRcr 1.72(1.00,2.95)* Referent 1.93(1.13,3.29)* 1.67(1.00,2.80) 
eGFRcys 0.97(0.58,1.62) Referent 1.20(0.76,1.91) 1.42(0.91,2.21) 
eGFRcr-
cys 
0.95(0.58,1.54) Referent 1.03(0.65,1.65) 1.32(0.85,2.04) 
cystatin C 0.71(0.43,1.16) Referent 0.83(0.53,1.31) 1.20(0.79,1.80) 
B2M 0.54(0.31,0.93)* Referent 1.29(0.82,2.01) 1.51(0.98,2.32) 
Model 2 
eGFRcr 1.77(1.03,3.04)* Referent 1.89(1.11,3.23)* 1.56(0.93,2.63) 
eGFRcys 0.96(0.57,1.61) Referent 1.21(0.76,1.92) 1.28(0.82,2.02) 
eGFRcr-
cys 
0.99(0.60,1.61) Referent 1.05(0.66,1.68) 1.23(0.79,1.91) 
cystatin C 0.70(0.43,1.15) Referent 0.84(0.53,1.32) 1.09(0.72,1.66) 
B2M 0.53(0.31,0.91)* Referent 1.28(0.82,2.00) 1.35(0.87,2.09) 
Note:  
*p<0.05, **p<0.01, ***p<0.001 
Model 1 adjusted for age, gender, race, ARIC visit center, education level, BMI, smoking status, alcohol 
drinking status, LDL level, HDL level, systolic blood pressure, anti-hypertensive medication, lowering-
cholesterol medication, diabetes, prevalent coronary heart disease and prevalent stroke.  
Model 2 adjusted for covariates in Model 1 plus FGF23, PTH, calcium and phosphorus. 
Quartiles for kidney function markers: 
eGFRcr (mL/min/1.73 m2): Q1: ≥ 105.64, Q2: 97.44-<105.64, Q3: 88.68-< 97.44, Q4: < 88.68 
eGFRcys (mL/min/1.73 m2): Q1: ≥ 104.88, Q2: 93.75-<104.88, Q3: 79.05-< 93.75, Q4: < 79.05 
eGFRcr-cys (mL/min/1.73 m2): Q1: ≥106.64, Q2: 96.69-<106.64, Q3: 85.19-< 96.69, Q4: < 85.19 
cystatin C (mg/L): Q1: <0.76, Q2: 0.76-< 0.85, Q3: 0.85-< 0.97, Q4: ≥0.97 
B2M (mg/L): Q1: <1.62, Q2: 1.62-< 1.84, Q3: 1.84-< 2.11, Q4: ≥2.11 
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Table S 5 Subgroup analyses on the association with incident PAD and CLI across 
quartiles of cystatin C and beta-2 microglobulin (1
st




Level Q1 Q2 Q3 Q4 p-
value 















<65 Referent 1.28(0.92-1.78) 1.01(0.71-1.44) 2.18(1.59-2.99) 0.022 
 ≥65 Referent 2.67(0.78-9.19) 3.22(0.96-10.85) 4.10(1.27-13.24)  
       
Sex Female Referent 1.24(0.80-1.92) 1.09(0.69-1.73) 2.02(1.35-3.03) 0.993 
 Male Referent 1.30(0.82-2.07) 1.06(0.66-1.72) 1.98(1.27-3.08)  
       
Race White Referent 1.54(1.00-2.38) 1.37(0.88-2.14) 2.52(1.66-3.83) 0.318 
 Black Referent 1.08(0.67-1.75) 0.78(0.45-1.34) 1.51(0.97-2.36)  
       
Ever 
smoking 
No Referent 1.18(0.65-2.13) 1.16(0.63-2.11) 2.33(1.36-3.98) 0.000 
 Yes Referent 1.46(1.01-2.12) 1.22(0.82-1.80) 2.34(1.64-3.34)  
       
Diabetes No Referent 1.48(0.97-2.27) 1.26(0.81-1.96) 2.57(1.71-3.87) 0.220 
 Yes Referent 1.10(0.68-1.78) 0.91(0.55-1.51) 1.44(0.93-2.22)  
       
Hypertensi
on 
No Referent 1.21(0.78-1.86) 1.06(0.67-1.67) 1.76(1.15-2.71) 0.000 
 Yes Referent 1.39(0.88-2.20) 1.13(0.71-1.82) 2.23(1.47-3.39)  
       
Prevalent 
CVD 
No Referent 1.30(0.93-1.82) 0.94(0.65-1.36) 2.09(1.50-2.90) 0.077 
 Yes Referent 1.18(0.47-2.94) 1.78(0.76-4.17) 1.86(0.84-4.12)  








<65 Referent 1.21(0.86-1.71) 1.65(1.19-2.30)  2.77(2.02-3.79) 0.015 











       
Sex Female Referent 1.32(0.80-2.18) 1.82(1.14-2.89) 2.55(1.64-3.96) 0.869 
 Male Referent 1.25(0.81-1.94) 1.67(1.09-2.54) 2.81(1.88-4.20)  
       
Race White Referent 1.34(0.85-2.10) 1.99(1.31-3.02) 3.01(2.00-4.53) 0.599 
 Black Referent 1.29(0.78-2.12) 1.35(0.79-2.31) 2.33(1.48-3.66)  







No Referent 0.72(0.35-1.46) 1.48(0.82-2.67) 2.56(1.50-4.35) 0.000 
 Yes Referent 1.56(1.07-2.29) 1.87(1.29-2.71) 2.74(1.92-3.92)  
       
Diabetes No Referent 1.33(0.85-2.08) 2.04(1.34-3.09) 3.33(2.22-4.99) 0.164 
 Yes Referent 1.32(0.80-2.18) 1.39(0.85-2.28) 2.00(1.29-3.10)  
       
Hypertensi
on 
No Referent 1.34(0.85-2.13) 1.80(1.16-2.80) 2.63(1.70-4.06) 0.000 
 Yes Referent 1.20(0.75-1.93) 1.64(1.05-2.55) 2.70(1.79-4.06)  
       
Prevalent 
CVD 
No Referent 1.21(0.84-1.73) 1.70(1.21-2.39) 2.78(2.00-3.87) 0.550 
 Yes Referent 1.73(0.73-4.07) 1.94(0.85-4.42) 2.53(1.19-5.37)  












Age <65 Referent 1.61(0.95-2.73) 1.24(0.70-2.19) 1.74(1.03-2.95) 0.196 
 ≥65 Referent 1.13(0.28-4.56) 1.61(0.42-6.13) 1.99(0.57-6.92)  
       
Sex Female Referent 1.28(0.66-2.51) 1.22(0.62-2.41) 1.65(0.89-3.06) 0.912 
 Male Referent 1.57(0.74-3.30) 1.17(0.53-2.60) 1.52(0.72-3.20)  
       
Race White Referent 2.16(0.93-5.02) 1.62(0.68-3.87) 2.02(0.87-4.68) 0.590 
 Black Referent 1.07(0.56-2.06) 1.03(0.52-2.05) 1.48(0.81-2.72)  
       
Ever 
smoking 
No Referent 0.99(0.44-2.22) 0.80(0.34-1.88) 1.71(0.82-3.54) 0.081 
 Yes Referent 1.89(1.01-3.54) 1.67(0.87-3.20) 1.79(0.96-3.34)  
       
Diabetes No Referent 1.51(0.68-3.37) 1.14(0.49-2.68) 1.97(0.90-4.30) 0.699 
 Yes Referent 1.41(0.75-2.65) 1.28(0.67-2.43) 1.38(0.76-2.52)  
       
Hypertensi
on 
No Referent 1.30(0.57-2.94) 1.24(0.53-2.92) 1.51(0.66-3.47) 0.000 
 Yes Referent 1.53(0.83-2.82) 1.19(0.63-2.27) 1.62(0.90-2.92)  
       
Prevalent 
CVD 
No Referent 1.55(0.91-2.63) 1.08(0.61-1.92) 1.76(1.03-3.01) 0.201 
 Yes Referent 0.81(0.20-3.32) 1.73(0.52-5.77) 1.06(0.35-3.25)  









<65 Referent 1.69(0.95-2.99) 2.20(1.25-3.86) 2.70(1.57-4.65) 0.105 
 ≥65 Referent 7.08(0.86-
58.26) 
9.42(1.21-73.12) 7.20(0.93-55.79)  








Sex Female Referent 2.13(0.97-4.68) 2.11(0.97-4.57) 2.85(1.38-5.85) 0.600 
 Male Referent 1.66(0.80-3.48) 2.68(1.32-5.41) 2.22(1.08-4.56)  
       
Race White Referent 2.86(1.07-7.70) 3.65(1.41-9.47) 3.36(1.29-8.77) 0.562 
 Black Referent 1.48(0.74-2.95) 1.82(0.90-3.66) 2.41(1.29-4.52)  
       
Ever 
smoking 
No Referent 0.39(0.13-1.23) 1.30(0.59-2.88) 1.91(0.94-3.90) 0.001 
 Yes Referent 3.79(1.85-7.79) 3.69(1.79-7.63) 3.25(1.57-6.72)  
       
Diabetes No Referent 1.26(0.51-3.11) 2.24(0.98-5.09) 2.97(1.32-6.66) 0.184 
 Yes Referent 2.46(1.26-4.83) 2.52(1.28-4.96) 2.26(1.18-4.33)  
       
Hypertensi
on 
No Referent 2.27(0.96-5.39) 1.85(0.75-4.57) 2.73(1.14-6.54) 0.000 
 Yes Referent 1.62(0.81-3.23) 2.63(1.38-5.01) 2.50(1.33-4.67)  
       
Prevalent 
CVD 
No Referent 1.70(0.95-3.03) 2.21(1.26-3.87) 2.59(1.49-4.53) 0.581 
 Yes Referent 3.71(0.74-
18.68) 
4.28(0.89-20.71) 3.11(0.71-13.66)  
Note:  
HRs were calculated from linear combinations of coefficients in the model with interaction terms based on 
model 2, and p-value was obtained from likelihood ratio test comparing models with and without the 
interaction term. 
Detailed descriptions on covariates included in the model for different stratification variables can be found 
under Table S3. 
Quartiles for cystatin C and B2M: 
Cystatin C (mg/L): Q1: <0.76, Q2: 0.76-< 0.85, Q3: 0.85-< 0.97, Q4:≥0.97 
B2M (mg/L): Q1: <1.62, Q2: 1.62-< 1.84, Q3: 1.84-< 2.11, Q4: ≥2.11 
Abbreviation: 
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Birthdate: May 11 1990 
Birthplace: Shanghai, China 
Mobile: +1 (443) 362-9254  
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EDUCATION 
Master of Science                 Expected May 2016 
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA 
Major: Epidemiology, with concentration in cardiovascular disease 
Bachelor of Medicine                          July 2014 
Fudan University Shanghai Medical College, Shanghai, China 
Major: Preventive Medicine 
Donghua University, Shanghai, China                                          Sept. 2008- July 2009 
Major: Electrical Engineering 
 
MANUSCRIPT & PUBLICATION 
Yang C., Kwak L., Ballew S., et al. Kidney function, bone-mineral metabolism markers, and 
peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. Manuscript 
in preparation  
Xu F., Yang C., Chai W.H., et al. (2012) Childhood Atopic Dermatitis and Household 
Environmental Risk Factors- A Cross-sectional Study in 4784 children in Jiading District, 
Shanghai, Journal of Environment and Health, 2012, 29(6), 23-26. 
 
CONFERENCE PRESENTATION 
American Heart Association Epidemiology and Prevention, Lifestyle and            Mar 2 2016       
Cardiometabolic Health 2016 Scientific Sessions (AHA-EPI), Phoenix, AZ 
Moderated presentation of abstract: Kidney function, bone-mineral metabolism markers, and 
peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. 
 
RESEARCH & TEACHING EXPERIENCE 
Teaching Assistant                                                      Mar 2016-  
for Stata Programming 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
Instructors: Profs. Allan Massie and Dorry Segev 
·Instructed students to master programming skills in data management  
and automated table-making using Stata 
·Graded homework 
Research Assistant                                                        Jul 2015- 
Department of Epidemiology, 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
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Supervisor: Prof. Kunihiro Matsushita 
·Extracted literature 
·Summarized diseases' revised Current Procedural Terminology (CPT) codes  
·Analyzed ARIC study data and drafted a manuscript 
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for Statistical Methods in Public Health I to III series  
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
Instructors: Profs. Marie Diener-West and Karen Bandeen-Roche 
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Epidemiological Research Group on Transplantation (ERGOT),  
Johns Hopkins University School of Medicine, Baltimore, MD.  
Supervisor: Prof. Allan Massie 
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·Conducted validation check and reshaped wide dataset into long format  
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Department of Environmental Health, School of Public Health,  
Fudan University, Shanghai, China.  
Supervisor: Prof. Zhuohui Zhao 
·Collaborated on data collection and validation on a community-based cross-sectional survey 
in over 10,000 children aged 3-12 years old in three communities in Shanghai, China 
·Analyzed study data and published the results in a Chinese core journal  
 
AWARDS & HONORS 
·Master’s Tuition Scholarship from Johns Hopkins Bloomberg School of Public Health 2015              
·Renmin Scholarship from Fudan University (for each academic year from 2011 through 
2014) (Top 20%) 
·Honor of Outstanding Student from Fudan University 2012 (Top 5%) 
·Honor of Outstanding Youth Volunteer from Fudan University 2012 (Top 1%) 




Program Intern, Jing’an District CDC, Shanghai, China                  Feb 2014- Apr 2014     
·Assisted completing Jing’an District 2013-2014 Annual Vital Statistics Report 
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·Fudan University, GPA: 3.31/ 4, major GPA: 3.52/ 4 (rank 4/40) 
·Donghua University, GPA: 3.2/ 4 (rank 41/396) 
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·Certificate: SAS Certified Base Programmer for SAS 9 
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